Abstract
Importance Randomized controlled trials in nutrition (RCTN) face unique challenges such as the influence of participants’ background diets and varying adherence to the intervention, factors that are difficult to quantify and can mask true intervention effects. However, the exact impact of these factors remains unclear.
Objective To quantify the impact of background diet and adherence, estimated using validated nutritional biomarkers of flavanol intake, on the outcomes of a large-scale RCTN.
Design, Setting, and Participants This study was nested within the COcoa Supplement and Multivitamin Outcomes Study (COSMOS; NCT02422745), a randomized, double-blind, placebo-controlled, 2×2 factorial trial conducted among 21,442 older adults in the United States. Analyses focused on participants (n=6,532) in the placebo and cocoa-extract intervention arms who had available biospecimens and outcome data.
Exposures Daily supplementation with a cocoa flavanol (CF).
Main Outcomes and Measures We used validated flavanol biomarkers in urine to assess background dietary flavanol intake and adherence to the cocoa extract intervention. Outcomes included total cardiovascular disease (CVD) events, CVD mortality, all-cause mortality, and major CVD events. Hazard ratios (HRs) with 95% CIs were estimated using intention-to-treat, per-protocol, and biomarker-based analyses.
Results Of the 6,532 participants, 20% in both the placebo and intervention arms had a background flavanol intake similar to that provided by the intervention; only 5% had no background flavanol intake. In the intervention group, 33% of participants were not adherent based on expected biomarker levels, that was larger than the15% estimated based on self-reported pill-taking. Accounting for biomarker-estimated background diet and adherence resulted in a significant impact on effect sizes. For total CVD events, the HR (95% CI) of 0.79 (0.59-1.05) in the per-protocol analysis (PP), was reduced to 0.65 (0.47-0.89) in the biomarker-based analysis. Similar changes were observed for CVD mortality (from 0.51 (0.23; 1.14) to 0.44 (0.20; 0.97)), all-cause mortality (0.69 (0.45; 1.05) to 0.54 (0.37; 0.80)) and major CVD events (from 0.62 (0.43; 0.91) to 0.48 (0.31; 0.74)). Overall, biomarker-based analyses consistently produced stronger effect estimates than ITT and PP analyses that do not consider the impact of background diet or assess adherence using self-reported methods.
Conclusions and Relevance These results highlight the importance of considering diet and adherence in RCTN using nutritional biomarker-based analyses. This may help to improve consistency and reliability of outcomes of RTC testing nutritional interventions.
Competing Interest Statement
J.I.O. and H.S. are employed by Mars, Incorporated, a company engaged in flavanol research and flavanol-related commercial activities. H.D.S. has received investigator-initiated research support from Mars Edge, Pure Encapsulations, and Pfizer Inc., and honoraria and/or travel for lectures from the Council for Responsible Nutrition, BASF, NIH, and American Society of Nutrition during the conduct of the study. J.E.M. has received investigator-initiated research support from Mars Edge. G.G.C.K. has received an unrestricted grant from Mars. COSMOS is supported by an investigator-initiated grant from Mars Edge, a segment of Mars dedicated to nutrition research and products, which included infrastructure support and the donation of study pills and packaging.
Clinical Trial
NCT02422745
Funding Statement
COSMOS is supported by an investigator-initiated research grant from Mars Edge (JEM, HDS), a segment of Mars dedicated to nutrition research and products, which included infrastructure support and the donation of study pills and packaging. Pfizer Consumer Healthcare (now Haleon) provided support through the partial provision of study pills and packaging (JEM, HDS). COSMOS is also supported in part by grants AG050657, AG071611, EY025623, and HL157665 from the US National Institutes of Health (NIH), Bethesda, MD. The Women's Health Initiative (WHI) program is funded by the National Heart, Lung, and Blood Institute, NIH, US Department of Health and Human Services through contracts 75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, and 75N92021D00005.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The COSMOS trial and ancillary studies were reviewed and approved by Institutional Review Boards at Brigham and Women's Hospital/Mass General Brigham. The COSMOS website is www.cosmostrial.org. All participants provided informed consent. No identifiable information were used in this study
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Code is available from https://gitlab.act.reading.ac.uk/xb901875/biomarker-based-intervention. Data and associated documentation will be available to users only under a data-sharing agreement. Details on the availability of the study data to other investigators will be on our study website at https://cosmostrial.org/.
